Si Sun

发表

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer

Haiquan Chen, Hui Yu, Jialei Wang, 2019, OncoTargets and therapy.

Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients

Z. Shao, Si Sun, Jian Zhang, 2013, BMC Cancer.

Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors

Jin Li, Jun Qian, Si Sun, 2014, Cancer Chemotherapy and Pharmacology.

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Hui Yu, Jian-hua Chang, Jialei Wang, 2022, The oncologist.

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

S. Zhang, J. Ragaz, Si Sun, 2015, PloS one.

Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma

Hui Yu, Jian-hua Chang, Jialei Wang, 2019, Oncology Research and Treatment.

Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors

W. Peng, Xiao-dong Zhu, Si Sun, 2014, Journal of Cancer Research and Clinical Oncology.

Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

Si Sun, Ye Guo, Yizhen Liu, 2019, Cancer management and research.

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Si Sun, Xiaofeng Xu, Jian Zhang, 2011, BMC Cancer.

Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations

Hui Yu, Jialei Wang, Xingjiang Hu, 2022, Journal of Cancer Research and Clinical Oncology.

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors

Hui Yu, Jialei Wang, Si Sun, 2022, Frontiers in Immunology.

Efficacy and safety of Endostar ( recombinant human endostatin hormone ) combined with docetaxel as second-or third-line therapy for patients with non-small-cell lung cancer

Hui Yu, Jian-hua Chang, Jialei Wang, 2016 .

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Zhen Jia, Jian Zhang, Si Sun, 2011, BMC Cancer.

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Z. Shao, Jialei Wang, S. Fais, 2015, Journal of experimental & clinical cancer research : CR.

Association between CYP17A1 polymorphisms and response to abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review

Xiaoping Zhou, S. Shariat, Si Sun, 2018 .

Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer

Hui Yu, Jian-hua Chang, Jialei Wang, 2020, Translational lung cancer research.

A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib

Hui Yu, Jian-hua Chang, Jialei Wang, 2014, Medical Oncology.

The association between common genetic variant of microRNA-146a and cancer susceptibility.

Xiao-dong Zhu, Jing He, C. Mao, 2011, Cytokine.

REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression

Shenglin Huang, Hui Yu, Jian-hua Chang, 2019, Journal of Cancer Research and Clinical Oncology.

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice

Haiquan Chen, Hui Yu, Jian-hua Chang, 2019, Targeted Oncology.

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

D. Zhong, Si Sun, N. Zhao, 2014, Journal of Hematology & Oncology.

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Hui Yu, Jian-hua Chang, Jialei Wang, 2017, OncoTargets and therapy.

Meta-analysis of associations between interleukin-17 gene polymorphisms and risk of gastric cancer.

Hui Yu, Si Sun, Qing Xu, 2014, Asian Pacific journal of cancer prevention : APJCP.

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Z. Shao, Jialei Wang, S. Fais, 2015, Journal of Experimental & Clinical Cancer Research.

The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects

Hui Yu, Jialei Wang, Xiao-dong Zhu, 2010, Breast Cancer Research and Treatment.

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center

Haiquan Chen, Hui Yu, Jian-hua Chang, 2019, Front. Oncol..

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer

Hui Yu, Jian-hua Chang, Jialei Wang, 2017, Oncotarget.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

J. Ragaz, Bing-he Xu, Zefei Jiang, 2014, International journal of cancer.

Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen

Si Sun, W. Peng, Jun Cao, 2015, Oncotarget.

Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility

Lei Yao, Si Sun, C. Mao, 2011, Molecular Biology Reports.

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations

Hui Yu, Jialei Wang, Si Sun, 2021, Frontiers in Oncology.

NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.

N. Shire, Jian-hua Chang, Si Sun, 2023, Lung cancer.

Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor

Ying Lin, Hui Yu, Jialei Wang, 2023, Journal of Cancer Research and Clinical Oncology.

Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors

Jian-hua Chang, Jing Zhao, Si Sun, 2017, Oncotarget.

Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients

Xiao Yan Yang, Si Sun, Jian Zhang, 2012, Medical Oncology.

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer

Hui Yu, Jian-hua Chang, Jialei Wang, 2014, Cancer biology & therapy.

Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations

Hui Yu, Jialei Wang, Xingjiang Hu, 2022, Journal of Cancer Research and Clinical Oncology.

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Xueqin Chen, H Zhao, Changli Wang, 2023, Nature Cancer.

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Guangyu Liu, Z. Shao, Si Sun, 2014, International journal of nanomedicine.

Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study.

Jian-hua Chang, Si Sun, Juan Li, 2023, Lung cancer.

A phase II study of weekly nanoparticle albumin-bound paclitaxel combined with cisplatin in patients with metastatic breast cancer.

Si Sun, Yunhua Lu, Jian Zhang, 2012 .

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study

Hui Yu, Jian-hua Chang, Jialei Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer

Hui Yu, Jialei Wang, Si Sun, 2022, Thoracic cancer.

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis

Jialei Wang, Si Sun, J. Xiang, 2024, Thoracic cancer.